Market Research Logo

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
  • The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Overview
Therapeutics Development
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Stage of Development
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Therapy Area
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Indication
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Companies
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Universities/Institutes
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Companies Involved in Therapeutics Development
Ablynx NV
Agilvax Inc
Aridis Pharmaceuticals LLC
Aviragen Therapeutics Inc
Bavarian Nordic A/S
Celltrion, Inc.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Gene Techno Science Co., Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Johnson & Johnson
mAbxience S.A.
MedImmune LLC
Medivir AB
Mucosis B.V.
Navigen Pharmaceuticals, Inc.
NeuClone Pty Ltd
Novavax, Inc.
Regeneron Pharmaceuticals Inc
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
The International Biotechnology Center (IBC) Generium
Vaxart Inc
VBI Vaccines Inc
VLP Biotech, Inc.
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drug Profiles
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-0529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-0171 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTA-585 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-32T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-preF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNR-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GV-2311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-61187165AAA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-61187191AAA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-64400141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-8897 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA-RSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
presatovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccines - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RV-521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suptavumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SynGEM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Dormant Projects
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Discontinued Products
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Featured News & Press Releases
Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium
Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults
Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine
Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine
Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program
May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalized with a RSV infection
Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Ablynx NV, H2 2016
Pipeline by Agilvax Inc, H2 2016
Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Pipeline by Aviragen Therapeutics Inc, H2 2016
Pipeline by Bavarian Nordic A/S, H2 2016
Pipeline by Celltrion, Inc., H2 2016
Pipeline by Emergent BioSolutions Inc., H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by Gene Techno Science Co., Ltd., H2 2016
Pipeline by GenVec, Inc., H2 2016
Pipeline by Gilead Sciences, Inc., H2 2016
Pipeline by GlaxoSmithKline Plc, H2 2016
Pipeline by iBio, Inc., H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by mAbxience S.A., H2 2016
Pipeline by MedImmune LLC, H2 2016
Pipeline by Medivir AB, H2 2016
Pipeline by Mucosis B.V., H2 2016
Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
Pipeline by NeuClone Pty Ltd, H2 2016
Pipeline by Novavax, Inc., H2 2016
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Pipeline by TechnoVax, Inc., H2 2016
Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Pipeline by Vaxart Inc, H2 2016
Pipeline by VBI Vaccines Inc, H2 2016
Pipeline by VLP Biotech, Inc., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report